CXCR2 receptor antagonists: A medicinal chemistry perspective

Current Topics in Medicinal Chemistry

Volumn 14, Issue 13, 2014, Pages 1590-1605

  Dwyer, Michael P ^a   Yu, Younong ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Chemokine; COPD; CXCR2; CXCR2 receptor antagonist; Gro (CXCL1); Interleukin 8 (IL 8 or CXCL8); medicinal chemistry

Indexed keywords

3,4 DIAMINOCYCLOBUT 3 ENE 1,2 DIONE; ARYLPROPIONIC ACID DERIVATIVE; CALCIUM ION; CHEMICAL COMPOUND; CHEMOKINE; CHEMOKINE RECEPTOR CCR2 ANTAGONIST; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CXCL1 CHEMOKINE; G PROTEIN COUPLED RECEPTOR; GLUCURONOSYLTRANSFERASE; INTERLEUKIN 8; MYELOPEROXIDASE; UNCLASSIFIED DRUG; CHEMOKINE RECEPTOR CCR2; MOLECULAR LIBRARY;

ARTHRITIS; ARTICLE; ASTHMA; CHEMOTAXIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); DRUG CLEARANCE; DRUG INDUSTRY; HUMAN; IC50; INFLAMMATORY DISEASE; LEUKOCYTE; MEDICINAL CHEMISTRY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RECEPTOR AFFINITY; REGULATORY MECHANISM; STRUCTURE ACTIVITY RELATION; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; METABOLISM; MOLECULAR LIBRARY; PHARMACOLOGY;

CHEMISTRY, PHARMACEUTICAL; HUMANS; MOLECULAR STRUCTURE; RECEPTORS, CCR2; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84907178392     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026614666140827144615     Document Type: Article

References (129)

1. Moser, B.; Wolf, M.; Walz, A.; Loetscher, P. Chemokines: multiple levels of leukocyte migration control. Trends Immunol., 2004, 25(2), 75-84.
2. Murphy, P. M. Neutrophil receptors for interleukin-8 and related CXC chemokines. Semin. Hematol., 1997, 34(4), 311-318.
3. Holmes, W. E.; Lee, J.; Kuang, W. J.; Rice, G. C.; Wood, W. I. Structure and functional expression of a human interleukin-8 receptor. Science, 1991, 253(5025), 1278-1280.
4. Murphy, P. M.; Tiffany, H. L. Cloning of complementary DNA encoding a functional human interleukin receptor. Science, 1991, 253(5025), 1280-1282.
5. Mukaida, N. Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases. Am. J. Physiol. Lung Cell Mol. Physiol., 2002, 284(10), L566-L577.
6. Traves, S.; Smith, S. J.; Barnes, P. J.; Donnelly, L. E. Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: a role for CXCR2. J. Leukoc. Biol. 2004, 76(12), 441-450.
7. Reutershan, J.; Morris, M. A.; Burcin, T. L.; Smith, D. F.; Chang, D.; Saprito, M. S.; Ley, K. Critical role of endothelial CXCR2 in LPS-induced neutrophil migration into the lung. J. Clin. Invest., 2006, 116(3), 695-702.
8. Walz, A.; Burgener, R.; Carr, B.; Baggiolini, M.; Kunkel, S. L.; Strieter, R. M. Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin-8. J. Exp. Med., 1991, 174(6), 1355-1362.
9. Wolf, M.; Delgado, M. B.; Jones, S. A.; Dewald, B.; Clark-Lewis, B.; Baggiolini, M. Granulocyte chemotactic protein 2 act via both IL-8 receptors, CXCR1 and CXCR2. Eur. J. Immunol., 1998, 28(1), 164-170.
10. Baggiolini, M.; Dewald, B.; Moser, B. Interleukin-8 and related chemotactic cytokines CXC and CC chemokines. Adv. Immunol., 1994, 55, 97-179.
11. White, J. R.; Lee, J. M.; Young, P. R.; Hertzberg, R. P.; Jurewicz, A. J.; Chaikin, M. A.; Widdowson, K. L.; Foley, J. J.; Martin, L. D.; Griswold, D. E.; Sarau, H. M. Identification of a potent, selective non-peptide antagonist that inhibits interleukin-8-induced neutrophil migration. J. Biol. Chem., 1998, 273(17), 10095-10098.
12. Strieter, R. M., Koch, A. E.; Antony, V. B.; Fick, R. B. Jr.; Standiford, T. J.; Kunkel, S. L. The immunopathology of chemotactic cytokines: The role of interleukin-8 and monocyte chemoattractant protein-1. J. Lab. Clin. Med., 1994, 123(2), 183-197.
13. Walz, A.; Dewald, B.; von Tscharner, V.; Baggiolini, M. Effects of the neutrophil-activating peptide NAP-2, platelet basic protein, connective tissue-activating peptide III and platelet factor 4 on human neutrophils. J. Exp. Med., 1989, 170(5), 1745-1750.
14. Thelen, M.; Peveri, P.; von Tsharaner. V.; Walz, A.; Baggiolini, M. Mechanism of neutrophil activation by NAF, a novel monocytederived peptide agonist. FASEB J., 1988, 2(11), 2702-2706.
15. Peveri, P.; Walz, A.; Dewald, B.; Baggiolini, M. A novel neutrophil-activating factor produced by human mononuclear phagocytes. J. Exp. Med., 1988, 167(5), 1547-1559.
16. Leonard, E. J.; Yoshimura, T.; Tanaka, S.; Raffeld, M. Neutrophil recruitment by intradermally injected neutrophil attractant/activation protein-1. J. Invest. Dermatol., 1991, 96(5), 690-694.
17. Pesci, A.; Balbi, B.; Majori, M.; Cacciani, G.; Bertacco, S.; Alciato, P.; Donner, C. F. Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease. Eur. Respir. J. 1998, 12(2), 380-386.
18. Keatings, V. M.; Collins, R. D.; Scott, D. M. Differences in interleukin-8 and tumor necrosis factor-888in induced sputum from patients with chronic obstructive pulmonary disease or asthma. J. Am. J. Respir. Crit. Care Med., 1996, 153(2), 530-534.
19. Pease, J. E.; Sabroe, I. The role of interleukin-8 and its receptors in inflammatory lung disease: implications for therapy. Am. J. Respir. Med. 2002, 1(1), 19-25.
20. Strieter, R. M.; Keane, M. P.; Burdick, M. D.; Sakkour, A.; Murray, L. A.; Belperio, J. A. The Role of CXCR2/CXCR2 Ligands in Acute Lung Injury. Curr. Drug Targ-Inflamm. Allergy, 2005, 4(3), 299-303.
21. Davis, P. B.; Drumm, M.; Konstan, M. W. Cystic Fibrosis. Am. J. Respir. Crit. Care Med., 1996, 154(5), 1229-1256.
22. Strieter, R. M., Burdick, M. D., Gomperts, B. N., Belperio, J. A., Keane, M. P. CXC chemokines in angiogenesis. Cytok. Growth Fact. Rev., 2005, 16(6), 593-609.
23. White, J. R.; Sarau, H. M. IL-8 receptor antagonist: basic research and clinical utility. In: Chemokine Biology-Basic Research and Clinical Application; Moser, B.; Letts, G. L.; Neote, K.; Eds.; Birkhaeuser Verlag: Basel, 2007; Vol. 2, pp. 89-102.
24. Chapman, R. W.; Phillips, J. E.; Hipkin, R. W.; Curran, A. K.; Lundell, D.; Fine, J. S. CXCR2 antagonists for the treatment of pulmonary disease. Pharmacol Therap., 2009, 121(1), 55-68.
25. Russo, R. C.; Garcia, C. C.; Teixeira, M. M.; Amara, F. A. The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases. Expert Rev. Clin. Immunol., 2014, 10(5), 593-619.
26. Cacalano, G.; Lee, J; Kikly, K.; et al. Neutrophil and B cell expansion in mice that lack the murine IL-8 receptor homolog. Science 1994, 265(5172), 682-684.
27. Allegretti, M.; Cesta, M. C.; Garin, A.; et al. Current status of chemokine receptor inhibitors in development. Immunol. Lett., 2012, 145(1-2), 68-78.
28. Wijtmans, M.; Scholten, D. J.; de Esch, I. J. P.; et al. Therapeutic targeting of chemokine receptors by small molecules. Drug Disc. Today Tech., 2012, 9(4), e229-e236.
29. Donnelly, L. E.; Barnes, P. J. Chemokine receptor CXCR2 antagonism to prevent airways inflammation. Drugs of the Future, 2011, 36(6), 465-472.
30. Busch-Peterson, J. Small molecule antagonists of the CXCR2 and CXCR1 chemokine receptors as therapeutic agents for the treatment of inflammatory diseases. Curr. Top. Med. Chem., 2006, 6(13), 1354-1362.
31. Bizzarri, C.; Beccari, A. R.; Bertini, R.; Cavicchia, M. R.; Giorgini, S.; Allegretti, M. ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as therapeutic targets. Pharmacol. Ther., 2006, 112(1), 139-149.
32. Dwyer. M. P.; Biju, P. Discovery of 3, 4-diaminocyclobut-3-ene-1, 2-dione-based CXCR2 receptor antagonists for the treatment of inflammatory disorders. Curr. Top. Med. Chem., 2010, 10(13), 1339-1350.
33. Mihara, K.; Wijkmans, J. Low molecular weight CXCR2 antagonists as promising therapeutics. In: Chemokine Receptor as Drug Targets; Smit, M. J.; Lira, S. A.; Leurs, R.; Eds.; Wiley-VCG Verlag GmbH & KgaA: Weinheim, 2011; Vol. 46, pp. 279-299.
34. Busch-Petersen, J.; Wang, Y. Phenol-containing antagonists of the CXCR2 receptor. Expert Opin. Ther. Patents, 2008, 18(6), 629-637.
35. Dwyer, M. P.; Yu, Y. CXCR2 modulators: a patent review (2009-2013). Expert Opin. Ther. Patents, 2014, 24(5), 519-534.
36. Widdowson, K.; Nie, H.; Jurewicz, A. J.; Hertzberg, R. P.; Sarau, H. M.; Foley, J. J.; Lee, J.; White, J. R.; Veber, D. F. The role of the anionic groups in the receptor binding or interleukin-8 antagonists. Lett. Peptide Sci., 1998, 5(2-3), 235-239.
37. Widdowson, K.; Veber, D. F.; Jurewicz, A. J.; Nie, H.; Hertzberg, R. P.; Holl, W.; Sarau, H. M. Discovery and characterization of potent, small molecule interleukin-8B receptor antagonists. In Peptides 1996; Ramage, R.; Epton, R.; Eds.; Mayflower Scientific: Kingswinford, 1998; pp. 87-90.
38. Jin, Q.; Nie, H.; McCleland, B. W.; Widdowson, K. L.; Palovich, M. R.; Elliott, J. D.; Goodman, R. M.; Burman, M.; Sarau, H. M.; Ward, K. W.; Nord, M.; Orr, B. M.; Gorycki, P. D.; Busch-Petersen, J. Discovery of potent and orally bioavailable N, N'-diarylurea antagonists for the CXCR2 chemokine receptor. Bioorg. Med. Chem. Lett., 2004, 14(17), 4375-4378.
39. Sarau, H. M.; Widdowson, K. L.; Palovich, M. R.; White, J. R.; Underwood, D. D; Griswold, D. E. Interleukin-8 receptor (CXCR2) antagonists. Prog. Respir. Res., 2001, 31, 293-296.
40. Auten, R. L.; Richardson, R. M.; White, J. R.; Mason, S. N.; Vozzelli, M. A.; Whorton, M. H. Nonpeptide CXCR2 antagonist prevents neutrophil accumulation in hyperoxia-exposed newborn rats. J. Pharmcol. Exp. Ther., 2001, 299(1), 90-95.
41. Bradley, M. E.; Bond, M. E.; Brown, Z.; Charlton, S. J. SB265610 is an allosteric, inverse agonist at the human CXCR2 receptor. Brit. J. Pharmacol., 2009, 158(1), 328-338.
42. Widdowson, K. L.; Elliott, J. D.; Veber, D. F.; Nie, H.; Rutledge, M. C.; McCleland, B. W.; Xiang, J.-N.; Jurewicz, A. J.; Hertzberg, R. P.; Foley, J. J.; Griswold, D. E.; Martin, L.; Lee, J. M.; White, J. R.; Sarau, H. M. Evaluation of Potent and Selective Small-Molecule Antagonists for the CXCR2 Chemokine Receptor. J. Med. Chem., 2004, 47(6), 1319-1321.
43. Podolin, P. L.; Bolognese, B. J.; Foley, J. J.; Schmidt, D. B.; Buckley, P. T.; Widdowson, K. L.; Jin, Q.; White, J. R.; Lee, J. M., Goodman, R. B.; Hagen, T. R.; Kajikawa, O.; Marshall, L. A.; Hay, D. W. P.; Sarau, H. M. A potent and selective nonpeptide antagonist of CXCR2 inhibits acute and chronic models of arthritis in the rabbit. J. Immunol., 2002, 16(11), 6435-6444.
44. Benson, G. M.; Grimsditch, D. C.; Piercy, V.; Vidgeon-Hart, M.; Groot, P. H. E.; Suckling, K.; Sarau, H. M.; Foley, J. J.; Jin, Q.; Palovich, M.; Widdowson, K. L. A CXCR2 antagonist, SB-332235, reduces artherosclerosis in LDL receptor deficient mice. Artherosclerosis, 2005, 181, 419.
45. Stevenson, C. S.; Coote, K.; Webster, R.; Johnston, H.; Atherton, H. C.; Nicholls, A.; Giddings, J.; Sugar, R.; Jackson, A.; Press, N. J.; Brown, Z.; Butler, K.; Danahay, H. Characterization of cigarette smoke-induced inflammatory and mucus hypersecretory changes in rat lung and the role of CXCR2 ligands in mediating this effect. Am. J. Physiol. Lung Cell Mol. Physiol., 2005, 288(3, pt1), L514-L522.
46. Carpenter, D. C.; Rumsey, W. M.; Busch-Peterson, J.; Sarau, H. M.; Salmon, M. The selective CXCR2 receptor antagonist SB-656933 inhibits CXCL1-induced neutrophil CD11b expression in human whole blood. Eur. Resp. Symp., September 2004. Eur. Resp. J., 2004, 24(suppl 48), 218s.
47. Nicholson, G. C.; Tennant, R. C.; Carpenter, D. C.; Sarau, H. M.; Kon, O. M.; Barnes, P. J.; Salmon, M.; Vessey, R. S.; Tal-Singer, R.; Hansel, T. T. A novel flow cytometric assay of human whole blood neutrophil and monocyte CD11b levels: Upregulation by chemokines is related to receptor expression, comparison of neutrophil shape change, and effects of a chemokine receptor (CXCR2) antagonist. Pulmon. Pharm. Ther. 2007, 20(1), 52-59.
48. Salmon, M.; Carpenter, C. J.; DeHaas, C. J.; Tal-Singer, R.; Sarau, H. M.; Underwood, D. C. Inhibition of LPS-induced neutrophil recruitment in the lung correlates with modulation of neutrophil CD11b expression using the selective CXCR2 receptor antagonist SB-656933. Eur. Resp. Symp., September 2004. Eur. Resp. J. 2004, 24(suppl 48), 218s.
49. Kruidenier, L.; Lione, L. A.; McCleary, S.; Vidgeon-Hart, P. M.; Stretton, J. G.; Ashmeade, X.; Lee, K.; Busch-Petersen, J.; Schwartz, S. I.; McLean, P. G. A selective CXCR2 receptor antagonist, SB656933-AAA reduces disease symptomology and ulceration in a DNBS rat model of colitis. Digestive Disease Weekly 2007, May 20 (Abs S1603).
50. Horuk, R. Chemokine receptor antagonists: overcoming development hurdles. Nat. Rev. Drug Discov., 2009, 8, 23-33.
51. Lazaar, A. L.; Sweeney, L. E.; MacDonald, A. J.; Alexis, N. E.; Chen, C.; Tal-Singer, R. SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans. Br. J. Clin. Pharmacol., 2011, 72(2), 282-293.
52. Moss, R. B.; Mistry S. J.; Konstan M. W.; Pilewski, J. M.; Kerem, E.; Tal-Singer, R.; Lazaar, A. L. Safety and early treatment effects of the CXCR2 receptor antagonist SB-656933 in patients with cystic fibrosis. J. Cystic Fibr., 2013, 12(3), 241-248.
53. Bloomer, J. C.; Nash, M.; Webb, A.; Miller, B. E.; Lazaar, A. L.; Beaumont, C.; Guiney, W. J. Assessment of potential drug interactions by characterization of human drug metabolism pathways using non-invasive bile sampling. Br. J. Pharmacol., 2012, 75(2), 488-496.
54. Miller, B. E.; Smart, K.; Mistry, S.; Ambery, C. L.; Bloomer, J. C.; Connolly, P.; Sanderson, D.; Shreeves, T.; Smith, R.; Lazaar, A. L. The pharmacokinetics of conventional and bioenhanced tablet formulations of danirixin (GSK1325756) following oral administration in healthy, elderly, human volunteers. Eur. J. Drug Metab. Pharmocokinet. 2014, 39(3), 173-181.
55. Investigation of safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical efficacy of oral danirixin in symptomatic COPD subjects with mild to moderate airflow limitation at risk for exacerbations (NCT02130193). http://clinicaltrials. gov/, [Accessed May 25, 2014].
56. Merritt, J. R.; Rokosz, L. L.; Nelson, K. H.; Kaiser, B.; Wang, W.; Stauffer, T. M.; Ozgur, L. E.; Li, G.; Baldwin, J. J.; Dwyer, M. P.; Chao, J.; Taveras, A. Synthesis and structure-activity relationships of 3, 4-diaminocyclobut-3-ene-1, 2-dione CXCR2 antagonists. Bioorg. Med. Chem. Lett., 2006, 16(15), 4107-4110.
57. McCleland, B. W.; Elliott, J. D.; Palovich, M. R.; Schmidt, D. M.; Sarau, H. M.; Foley, J. J.; Burman, M., Widdowson, K. Synthesis and characterization of a novel nonurea series of potent CXCR2 antagonists. 225th ACS National Meeting, New Orleans, LA, United States, March 23-27, 2003.
58. McCleland, B. W.; Davis, R. S.; Palovich, M. R.; Widdowson, K. L.; Werner, M. L.; Burman, M.; Foley, J. J.; Schmidt, D. B.; Sarau, H. M.; Rogers, M.; Salyers, K. L.; Gorycki, P. D.; Roethke, T. J.; Stelman, G. J.; Azzarano, L. M.; Ward, K. W.; Busch-Petersen, J. Comparison of N, N'-diarylsquaramides and N, N'-diarylureas as antagonists of the CXCR2 chemokine receptor. Bioorg. Med. Chem. Lett., 2007, 17(6), 1713-1717.
59. Dwyer, M. P.; Yu, Y.; Chao, J.; Aki, C.; Chao, J.; Biju, P.; Girijavallabhan, V.; Rindgen, D.; Bond, R.; Mayer-Ezel, R.; Jakway, J.; Hipkin, R. W.; Fossetta, J.; Gonsiorek, W.; Bian, H.; Fan, X.; Terminelli, C.; Fine, J.; Lundell, D.; Merritt, J. R.; Rokosz, L. L.; Kaiser, B.; Li, G.; Wang, W.; Stauffer, T. M.; Ozgur. L. E.; Taveras, A. G. Discovery of 2-Hydroxy-N, N-dimethyl-3-{2-[[(R)-1-(5-methylfuran-2-yl)propyl]amino]-3, 4-dioxo-cyclobut-1-enylamino}benzamide (SCH 527123): A Potent, Orally Bioavailable CXCR2/CXCR1 Receptor Antagonist J. Med. Chem., 2006, 49(26), 7603-7603.
60. Gonsiorek, W.; Fan, X.; Hesk, D.; Fossetta, J.; Qiu, H.; Jakway, J.; Billah, M.; Dwyer, M.; Chao, J.; Deno, G.; Taveras, A.; Lundell, D. J.; Hipkin, R. W. Pharmacological Characterization of Sch 527123, a Potent Allosteric CXCR1/CXCR2 Antagonist. J. Pharm. Exp. Ther., 2007, 322(2), 477-485.
61. Chapman, R. W.; Minnicozzi, M.; Celly, C. S.; Phillips, J. E.; Kung, T. T.; Hipkin, R. W.; Fan, X.; Rindgen, D.; Deno, G.; Bond, R.; Gonsiorek, W.; Billah, M. M.; Fine, J. S.; Hey, J. A. A Novel, Orally Active CXCR1/CXCR2 Receptor Antagonist, Sch527123, Inhibits Neutrophil Recruitment, Mucus Production, and Goblet Cell Hyperplasia in Animal Models of Pulmonary Inflammation. J. Pharm. Exp. Ther., 2007, 322(2), 486-493.
62. Thatcher, T. H.; McHugh, N. A.; Egan, R. W.; Chapman, R. W.; Hey, J. A.; Turner, C. K.; Redonnet, M. R.; Seweryniak, K. E.; Sime, P. J.; Phipps, R. P. Role of CXCR2 in cigarette smoke-induced inflammation. Am. J. Physiol. Lung Cell Mol. Physiol. 2005, 289(10), L322-L328.
63. Taveras, A. G.; Billah, M.; Lundell, D.; Kreutner, W.; Jakway, J.; Bober, L. A.; Chao, J.; Biju, P., Yu, Y. Combination treatments for chemokine-mediate diseases. WO 080053A1, 2003.
64. Holz, O.; Khalilieh, S.; Ludwig-Sengpiel, A.; Watz, H.; Stryszak, P.; Soni, P.; Tsai, M.; Sadeh, J.; Magnussen, H. SCH 527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. Eur. Respir. J., 2010, 35(3), 564-570.
65. Holz, O.; Tal-Singer, R.; Kanniess, F.; Simpson, K. J.; Gibson, A.; Vessey, R. S. J.; Janicki, S.; Magnussen, H.; Jorres, R. A.; Richter, K. Validation of the human ozone challenge model as a tool for assessing anti-inflammatory drugs in early development. J. Clin. Pharm., 2005, 45(5), 498-503.
66. Nair, P.; Gaga, M.; Zervas, E.; Alagha, K.; Hargreave, F. E.; O'Byrne, P. M.; Stryszak, P.; Gann, L.; Sadeh, J.; Chanez, P. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. Clin. Exp. Allergy, 2012, 42(7), 1097-1103.
67. Seiberling, M.; Kamtchoua, T.; Strysak, P; Ma, Y.; Langdon, R. B.; Khalilieh, S. Humoral immunity and delayed hypersensitivity in healthy subjects treated for 30 days with MK-7123, a selective CXCR2 antagonist. Int. Immunopharm., 2013, 17(2), 178-183.
68. Long-Term Extension Study of the Effects of SCH 527123 in Subjects With Moderate to Severe COPD (NCT01006616, Study P05575AM2)(MK-7123-009-0). http://clinicaltrials. gov/, [Accessed May 25, 2014].
69. Singh, S.; Sadanandam, A.; Nannuru, K. C.; Varney, M. L.; Mayer-Ezell, R.; Bond, R.; Singh, R. K. Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis. Clin. Cancer Res., 2009, 15(7), 2380-2386.
70. Varney, M. L.; Singh, S.; Li, A.; Mayer-Ezell, R.; Bond, R.; Singh, R. K. Small molecule antagonists for CXCR2 and CXCR1 inhibit human colon cancer liver metastases Cancer Lett., 2011, 300(2), 180-188.
71. Ning, Y.; Labonte, M. J.; Zhang, W.; Bohanes, P. O.; Gerger, A.; Yang, D.; Benhaim, L.; Paez, D.; Rosenberg, D. O.; Nagulapalli Venkata, K. C.; Louie, S. G.; Petasis, N. A.; Ladner, R. D; Lenz, H.-J. The CXCR2 antagonist, SCH 527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models. Mol. Cancer. Ther., 2012, 11(6), 1353-1364.
72. Chao, J.; Taveras, A. G.; Chao, J.; Aki, C.; Dwyer, M.; Yu, Y.; Purakkattle, B.; Rindgen, D.; Jakway, J.; Hipkin, W.; Fosetta, J.; Fan, X.; Lundell, D.; Fine, J.; Minnicozzi, M.; Phillips, J.; Merritt, J. R. C(4)-Alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists. Bioorg. Med. Chem. Lett., 2007, 17(13), 3778-3783.
73. Min, S. H.; Wang, Y.; Gonsiorek, W.; Anilkumar, G.; Kozlowski, J.; Lundell, D.; Fine, J. S.; Grant, E. P. Pharmacological targeting reveals distinct roles for CXCR2/CXCR1 and CCR2 in a mouse model of arthritis. Biochem. Biophys. Res. Comm., 2010, 391(1), 1080-1086.
74. Yu, Y.; Dwyer, M. P.; Chao, J.; Aki, C.; Chao, J.; Purakkattle, B.; Rindgen, D.; Bond, R.; Mayer-Ezel, R.; Jakway, J.; Qiu, H.; Hipkin, R. W.; Fossetta, J.; Gonsiorek, W.; Bian, H.; Fan, X.; Terminelli, C.; Fine, J.; Lundell, D.; Merritt, J. R.; He, Z.; Lai, G.; Wu, M.; Taveras, A. G. Synthesis and structure-activity relationships of heteroaryl substituted-3, 4-diamino-3-cyclobut-3-ene-1, 2-dione CXCR2/CXCR1 receptor antagonists. Bioorg. Med. Chem. Lett., 2008, 18(4), 1318-1322.
75. Lai, G.; Merritt, J. R.; He, Z.; Feng, D.; Chao, J.; Czarniecki, M. F.; Rokosz, L. L.; Stauffer, T. M.; Rindgen, D.; Taveras, A. G. Synthesis and structure-activity relationships or new disubstituted phenylcontaining 3, 4-diamino-3-cyclobutene-1, 2-diones as CXCR2 receptor antagonists. Bioorg. Med. Chem. Lett., 2008, 18(6), 1864-1868.
76. Biju, P.; Taveras, A. G.; Dwyer, M. P.; Yu, Y.; Chao, J.; Hipkin, R. W.; Fan, X.; Rindgen, D.; Fine, J.; Lundell, D. Fluoroalkyl RR-side chain containing 3, 4-diamino-cyclobutenediones as potent and orally bioavailable CXCR2-CXCR1 dual antagonists. Bioorg. Med. Chem. Lett., 2009, 19(5), 1431-1433.
77. Liu, S.; Liu, Y; Wang, H.; Ding, Y.; Wu, H.; Dong, J.; Wong, A.; Chen, S.-H.; Li, G.; Chan, M.; Sawyer, N.; Gervais, F. G.; Henault, M.; Kargman, S.; Bedard, L. L.; Han, Y.; Friesen, R.; Lobell, R. B.; Stout, D. M. Design, synthesis, and evaluation of novel 3-amino-4-hydrazine-cyclobut-3-ene-1, 2-diones as potent and selective CXCR2 chemokine receptor antagonists. Bioorg. Med. Chem. Lett., 2009, 19(19), 5741-5745.
78. Aki, C.; Chao, J.; Ferreira, J. A.; Dwyer, M. P.; Yu, Y.; Chao, J.; Merritt, J. R.; He, Z.; Lai, G.; Wu, M.; Hipkin, R. W.; Fan, X.; Gonsiorek, W.; Fossetta, J.; Rindgen, D.; Fine, J.; Lundell, D.; Taveras, A. G.; Biju, P. Diaminocyclobutenediones as potent and orally bioavailable CXCR2 receptor antagonists: SAR in the phenolic amide region. Bioorg. Med. Chem. Lett., 2009, 19(15), 4446-4449.
79. Chao, J.; Taveras, A. G.; Aki, C. J. Synthesis of functionalized hydroxyl-thiophene motifs as amido-and sulfonamide-phenol bioisosteres. Tett. Lett., 2009, 50(35), 5005-5008.
80. Nie, H.; Widdowson, K. L.; Palovich, M. R.; Fu, W.; Elliott, J. D.; Bryan, D. L.; Burman, M.; Schmidt, D. B.; Foley, J. J.; Sarau, H. M.; Busch-Petersen, J. N, N'-Diarylcyanoguanidines as antagonists of the CXCR2 and CXCR1 chemokine receptors. Bioorg. Med. Chem. Lett., 2006, 16(21), 5513-5516.
81. Wang, Y.; Busch-Petersen, J.; Wang, F.; Ma, L.; Fu, W.; Kerns, J. K.; Jin, J.; Palovich, M. R.; Shen, J.-K.; Burman, M.; Foley, J. J.; Schmidt, D. B.; Hunsberger, G. E.; Sarau, H. M.; Widdowson, K. L. 3-Arylamino-2H-1, 2, 4-benzothiadiazin-5-ol 1, 1-dioxides as novel and selective CXCR2 antagonists. Bioorg. Med. Chem. Lett., 2007, 17(14), 3864-3867.
82. Biju, P.; Taveras, A.; Yu, Y.; Zheng, J.; Chao, J.; Rindgen, D.; Jakway, J.; Hipkin, R. W.; Fossetta, J.; Fan, X.; Fine, J.; Qiu, H.; Merritt, J. R.; Baldwin, J. J. 3, 4-Diamino-2, 5-thiadiazole-1-oxides as potent CXCR2/CXCR1 antagonists. Bioorg. Med. Chem. Lett., 2008, 18(1), 228-231.
83. Biju, P.; Yu, Y.; Aki, C.; Zheng, J.; Chao, J.; Dwyer, M. P.; Rindgen, D.; Bond, R.; Jakway, J.; Qiu, Hongchen; Hipkin, R. W.; Fossetta, J.; Gonsiorek, W.; Bian, H.; Fan, X.; Terminelli, C.; Fine, J.; Merritt, J. R.; He, Z.; Lai, G.; Wu, M.; Taveras, A. Synthesis and SAR investigation of 3, 4-diamino derivatives of thiadiazole-1-oxides as CXCR1-CXCR2 dual antagonists. Abstracts of Papers, 234th ACS National Meeting, Boston, MA, United States, August 19-23, 2007.
84. Biju, P.; Taveras, A. G.; Yu, Y.; Zheng, J.; Hipkin, R. W.; Fossetta, J.; Fan, X.; Fine, J.; Lundell, D. 3, 4-Diamino-1, 2, 5-thiadiazole as potent and selective CXCR2 antagonists. Bioorg. Med. Chem. Lett., 2009, 19(5), 1434-1437.
85. Anon. Novel Pyrimidine-based CXCR2 antagonists. Exp. Opin. Ther. Pat., 2004, 14(10), 1507-1510.
86. Baxter, A.; Cooper, A.; Kinchin, E.; Moakes, K.; Unitt, J.; Wallace, A. Hit-to-Lead studies: The discovery of potent, orally bioavailable thiazolopyrimidine CXCR2 receptor antagonists. Bioorg. Med. Chem. Lett., 2006, 16(4), 960-963.
87. Hunt, F.; Austin, C.; Austin, R.; Bonnert, R.; Cage, P.; Christie, J.; Christie, M.; Dixon, C.; Hill, S.; Jewell, R.; Martin, I.; Robinson, D.; Willis, P. SAR studies on thiazolo[4, 5-d]pyrimidine based CXCR2 antagonists involving a novel tandem displacement reaction. Bioorg. Med. Chem. Lett., 2007, 17(10), 2731-2734.
88. Walters, Iain A. S. Structure activity relationships of a series of thiazolopyrimidine based CXCR2 antagonists with additional CCR2b activity. Abstracts of Papers, 234th ACS National Meeting, Boston, MA, United States, August 19-23, 2007.
89. Walters, I.; Austin, C.; Austin, R.; Bonnert, R.; Cage, P.; Christie, M.; Ebden, M.; Gardiner, S.; Grahames, C.; Hill, S.; Hunt, F.; Jewell, R.; Lewis, S.; Martin, I.; Nicholls, D.; Robinson, D. Evaluation of a series of bicyclic CXCR2 antagonists. Bioorg. Med. Chem. Lett., 2008, 18(2), 798-803.
90. Nicholls, D. J.; Tomkinson, N. P.; Wiley, K. E.; Brammel, A.; Bowers, L.; Grahames, C.; Gaw, A.; Meghani, P.; Shelton, P.; Wright, T. J.; Mallinder, P. R. Identification of a putative intracellular allosteric antagonist binding-site in the CXC chemokines receptors 1 and 2. Mol. Pharmacol., 2008, 74(5), 1193-1202.
91. Molfino, N. A. Drugs in Clinical Development for Chronic Obstructive Pulmonary Disease. Respiration, 2005, 72(1), 105-112.
92. Fitzgerald, M. F.; Fox, J. C. Emerging trends in the therapy of COPD: novel anti-inflammatory agents in clinical development. Drug Disc. Today 2007, 12(11-12), 479-486.
93. Loh, L. C.; Vyas, B.; Kanabar, V.; Kemeny, D. M.; O'Connor, B. J. Inhaled endotoxin in healthy human subjects: A dose-related study on systemic effects and peripheral CD4+ and CD8+ T cells. Respir. Med., 2006, 100(3), 519-528.
94. Virtala, R.; Ekman, A. K.; Jansson, L; Westin, U.; Cardell, L. O. Airway inflammation evaluated in a human nasal lipopolysaccharide challenge model by investigating the effect of a CXCR2 inhibitor. Clin. Exp. Allergy, 2011, 42(4), 590-596.
95. Leaker, B. R.; Barnes, P. J.; O'Connor, B. Inhibition of LPSinduced airway neutrophilic inflammation in healthy volunteers with an oral CXCR2 antagonist. Respiratory Res., 2013, 14, 137/1-137/9.
96. Norman P. Evidence on the identity of the CXCR2 antagonist AZD-5069. Expert Opin. Ther. Patents, 2013, 23(1), 113-117.
97. A phase II study to evaluate the efficacy, safety, and tolerability of AZD5069 in patients with uncontrolled persistent asthma (NCT01704495, NIMBUS). http://clinicaltrials. gov/, [Accessed May 25, 2014].
98. Porter, D. W.; Bradley, M.; Brown, Z.; Canova, R.; Charlton, S.; Cox, B.; Hunt, P.; Lolarik, D.; Lewis, S.; O'Connor, D.; Reilly, J.; Spanka, C.; Tedaldi, L.; Watson, S. J.; Watson, S. J.; Wermuth, R.; Press, N. J. The discovery of potent, orally bioavailable pyrazolo and triazolopyrimidine CXCR2 receptor antagonists. Bioorg. Med. Chem. Lett., 2014, 24(1), 72-76.
99. Porter, D. W.; Bradley, M.; Brown, Z.; Charlton, S. J.; Cox, B.; Hunt, P.; Janus, D.; Lewis, S.; Oakley, P.; O'Connor, D.; Reilly, J.; Smith, N.; Press, N. J. The discovery of potent, orally bioavailable pyrimidine-5-carbonitrile-6-alkyl CXCR2 receptor antagonists. Bioorg. Med. Chem. Lett. 2014, 24(15), 3285-3290.
100. Salchow, K.; Bond, M. E.; Evans, S. C.; Press, N. J.; Charlton, S. J.; Hunt, P. A.; Bradley, M. E. A common intracellular allosteric binding site for antagonists of the CXCR2 receptor. Br. J. Pharm. 2010, 159(7), 1429-1439.
101. Burton, V. J.; Holmes, A. M.; Ciuclan, L. I.; Robinson, A.; Roger, J. S.; Jarai, G.; Pearce, A. C.; Budd, D. C. Attenuation of leukocyte recruitment via CXCR1/2 inhibition stops the progression of PAH in mice with genetic ablation of endothelial BMPR-II. Blood, 2011, 118(17), 4750-4758.
102. Ho, K.-K.; Auld, D. S.; Bohnstedt, A. C.; Conti, P.; Dokter, W.; Erickson, S.; Feng, D.; Inglese, J.; Kingsbury, C.; Kultgen, S. G.; Liu, R.-Q.; Masterson, C. M.; Ohlmeyer, M.; Rong, Y.; Rooseboom, M.; Roughton, A.; Samama, P.; Smit, M.-J.; Son, E.; Van der Louw, J.; Vogel, G.; Webb, M.; Wijkmans, J.; You, M. Imidazolylpyrimidine based CXCR2 chemokine receptor antagonists. Bioorg. Med. Chem. Lett., 2006, 16(10), 2724-2728.
103. Kruijf, P.; Heteren, J.; Lim, H. D.; Conti, P. G. M.; Van der Lee, M. M. C.; Bosch, L.; Ho, K.-K.; Auld, D.; Ohlmeyer, M.; Smit, M. J.; Wijkmans, J. C. H. M.; Zaman, G. J. R.; Smit, M. J.; Leurs, R. Nonpetidergic allosteric antagonists differently bind to the CXCR2 receptor. J. Pharmacol. Exp. Ther., 2009, 329(2), 783-790.
104. Kruijf, P.; Lim, H. D.; Roumen, L.; Renjaan, V. A.; Zhao, J.; Webb. M. L.; Auld, D. S.; Wijkmans, J. C. H. M.; Zaman, G. J. R.; Smit, M. J.; de Graaf, C.; Leurs, R. Identification of a novel allosteric binding site in the CXCR2 chemokine receptor. Mol. Pharmacol., 2011, 80(6), 1108-1118.
105. Bizzarri, C.; Pagliei, S.; Brandolini, L.; more here Selective inhibition of interleukin-8-induced neutrophil chemotaxis by ketoprofen isomers. Biochem. Pharmacol., 2001, 61(11), 1429-1437.
106. Allegretti, M.; Bertini, R.; Cesta, M. C.; Bizzarri, C.; Bitondo, R. D.; Cioccio, V. D.; Galliera, E.; Berdini, V.; Topai, A.; Zampella, G.; Russo, V.; Bello, N. D.; Nano, G.; Nicolini, L.; Locati, M.; Fantucci, P.; Florio, S.; Colotta, F. 2-Arylpropionic CXC Chemokine Receptor 1 (CXCR1) Ligands as Novel Noncompetitive CXCL8 Inhibitors. J. Med. Chem. 2005, 48(13), 4312-4331.
107. Bertini, R.; Allegretti, M.; Bizzarri, C.; Moriconi, A.; Locati, M.; Zampella, G.; Cervellera, M. N.; Di Cioccio, V.; Cesta, M. C.; Galliera, E.; Martinez, F. O.; Di Bitondo, R.; Troiani, G.; Sabbatini, V.; D'Anniballe, G.; Anacardio, R.; Cutrin, J. C.; Cavalieri, B.; Mainiero, F.; Strippoli, R.; Villa, P.; Di Girolamo, M.; Martin, F.; Gentile, M.; Santoni, A.; Corda, D.; Poli, G.; Mantovani, A.; Ghezzi, P.; Colotta, F. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc. Natl. Acad. Sci. USA, 2004, 101(24), 11791-11796.
108. Casilli, F.; Bianchini, A.; Gloaguen, I.; Biordi, L.; Alesse, E.; Festuccia, C.; Cavalieri, B.; Strippoli, R.; Cervellera, M. N.; Di Bitondo, R.; Ferretti, E.; Mainiero, F.; Bizzarri, C.; Colotta, F.; Bertini, R. Inhibition of interleukin-8 (CXCL8/IL-8) responses by repertaxin, a new inhibitor of the chemokine receptors CXCR1 and CXCR2. Biochem. Pharmacol. 2005, 69(3), 385-394.
109. Cavalieri, B.; Mosca, M.; Ramadori, P.; Perrelli, M.-G.; De Simone, L.; Colotta, F. Bertini, R.; Poli, G.; Cutrin, J. C. Neutrophil recruitment in the reperfused-injured rat liver was effectively attenuated by repertaxin, a novel allosteric non-competitive inhibitor of CXCL8 receptors: A therapeutic approach for the treatment of post-ischemic hepatic syndromes. Int. J. Immunopath. Pharm., 2005, 18(3), 475-486.
110. Cugini, D.; Azzollini, N.; Gagliardini, E.; Cassis, P.; Bertini, R.; Colotta, F.; Noris, M.; Remuzzi, G.; Benigni, A. Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion. Kidney Int., 2005, 67(5), 1753-1761.
111. Garau, A.; Bertini, R.; Colotta, F.; Casilli, F.; Bigini, P.; Cagnotto, A.; Mennini, T.; Ghezzi, P.; Villa, P. Neuroprotection with the CXCL8 inhibitor repertaxin in transient brain ischemia. Cytokine 2005, 30(3), 125-131.
112. Souza, D. G.; Bertini, R.; Vieira, A. T.; Cunha, F. Q.; Poole, S.; Allegretti, M.; Colotta, F.; Teixeira, M. M. Repertaxin, a novel inhibitor of rat CXCR2 function, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury. Br. J. Pharmacol., 2004, 143(1), 132-142.
113. Gorio, A.; Madaschi, L.; Zadra, G.; Marfia, G.; Cavalieri, B.; Bertini, R.; Di Giulio, A. M. Reparixin, an inhibitor of CXCR2 function, attenuates inflammatory responses and promotes recovery of function after traumatic lesion to the spinal cord. J. Pharmacol. Exp. Ther., 2007, 322(3), 973-981.
114. Leitner, J. M.; Mayr, F. B.; Firbas, C.; Spiel, A. O.; Steinlechner, B.; Novellini, R.; Jilma, B. Reparixin, a specific interleukin-8 inhibitor, has no effects on inflammation during endotoxemia. Int. J. Immunopath. Pharmacol., 2007, 20(1), 25-36.
115. Reparixin in Prevention of Delayed Graft Dysfunction after Kidney Transplantation (NCT00248040). http://clinicaltrials. gov/, [Accessed May 25, 2014].
116. Repertaxin in Prevention of Primary Graft Dysfunction after Lung Transplantation (NCT00224406). http://clinicaltrials. gov/, [Accessed May 25, 2014].
117. Moriconi, A.; Cesta, M. C.; Cervellera, M. N.; Aramini, A.; Coniglio, S.; Colagioia, S.; Beccari, A. R.; Bizzarri, C.; Cavicchia, M. R.; Locati, M.; Galliera, E.; Di Benedetto, P.; Vigilante, P.; Bertini, R.; Allegretti, M. Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2. J. Med. Chem., 2007, 50(15), 3984-4002.
118. Sablone, M. R.; Cesta, M. C.; Moriconi, A.; Aramini, A.; Bizzarri, C.; Di Giacinto, C.; Di Bitondo, R.; Gloaguen, I.; Aschi, M.; Crucianelli, M.; Bertini, R.; Allegretti, M. Structure-activity relationship of novel phenylacetic CXCR1 inhibitors. Bioorg. Med. Chem. Lett., 2009, 19(15), 4026-4030.
119. Moriconi, A.; Bigogno, C; Bianchini, G; Caligiuri, A.; Resconi, A.; Dondio, M. G.; D'Annibelle, G.; Allegretti, M. Aryltriflates as a neglected moiety in medicinal chemistry: A case study from a lead optimization of CXCL8 inhibitors. ACS Med. Chem. Lett., 2011, 2(10), 768-773.
120. Bertini, R.; Barcelos, L. S.; Beccari, A. R.; Cavalieri, B.; Moriconi, A.; Bizzarri, C.; Di Benedetto, P.; Di Giacinto, C.; Gloaguen, I.; Galliera, E.; Corsi, M. M.; Russo, R. C.; Andrade, S. P.; Cesta, M. C.; Nano, G.; Aramini, A.; Cutrin, J. C.; Locati, M.; Allegretti, M.; Texixeira, M. M. Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non-competitive allosteric inhibitor. Brit. J. Pharm., 2012, 165(2), 436-454.
121. Cutshall, N. S.; Ursino, R.; Kucera, K. A.; Latham, J.; Ihle, N. C. Nicotinamide N-oxides as CXCR2 antagonists. Bioorg. Med. Chem. Lett. 2001, 11(14), 1951-1954.
122. Cutshall, N. S.; Kucera, K. A.; Ursino, R.; Latham, J.; Ihle, N. C. Nicotinanilides as inhibitors of neutrophil chemotaxis. Bioorg. Med. Chem. Lett., 2002, 12(11), 1951-1954.
123. Maeda, D. Y.; Quinn, M. T.; Schepetkin, I. A.; Kirpotina, L. N.; Zebala, J. A. Nicotinamide glycolates antagonize CXCR2 activity through and intracellular mechanism. J. Pharmacol. Exp. Ther. 2010, 332(1), 145-152.
124. Li, J. J.; Carson, K. G.; Trivedi, B. K.; Yue, W. S; Ye, Q.; Glynn, R. A.; Miller, S. R.; Connor, D. T.; Roth, B. D.; Luly, J. R.; Low, J. E.; Heilig, D. J.; Yang, W.; Qin, S.; Hunt, S. Synthesis and structureactivity relationship of 2-amino-3-heteroaryl-quinoxalines as nonpeptide, small molecule antagonists for interleukin-8 receptor. Bioorg. Med. Chem., 2003, 11(17), 3777-3790.
125. Baxter, A.; Bennion, C.; Bent, J.; Boden, K.; Brough, S.; Cooper, A.; Kinchin, E.; Kindon, N.; McInally, T.; Mortimore, M.; Roberts, B.; Unitt, J. Hit-to-lead studies: The discovery of potent, orally bioavailable triazolethiol CXCR2 receptor antagonists. Bioorg. Med. Chem., 2003, 13(16), 2625-2628.
126. Winters, M. P.; Crysler, C.; Subasinghe, N.; Ryan, D.; Leong, L.; Zhao, S.; Donatelli, R.; Yurkow, E.; Mazzulla, M.; Boczon, L.; Manthey, C. L.; Molloy, C.; Raymond, H.; Murray, L.; McAlonan, L.; Tomczuk, B. Carboxylic acid bioisosteres acylsulfonamides, acylsulfamides, and sulfonylureas as novel antagonists of the CXCR2 receptor. Bioorg. Med. Chem. Lett., 2008, 18(6), 1926-1930.
127. Weidner-Wells, M. A.; Henninger, T. C.; Fraga-Spano, S. A.; Boggs, C. M.; Matheis, M.; Ritchie, D. M.; Argentieri, D. C.; Wachter, M. P.; Hlasta, D. J. Synthesis and structure-activity relationships of 3, 5-diarylisoxazoles and 3, 5-diaryl-1, 2, 4-oxadiazoles, novel classes of small molecule interleukin-8 (IL-8) receptor antagonists. Bioorg. Med. Chem. Lett., 2004, 14(16), 4307-4311.
128. Singh, R. K.; Varney, M. L. IL-8-expression in malignant melanoma: implications in growth and metastasis. Histol. Histopathol., 2000, 15(3), 843-849.
129. Hertzer, K. M.; Donald, G. W.; Hines, O. J. CXCR2: a target for pancreatic cancer treatment? Expert Opin. Ther. Targets, 2013, 17(6), 667-680.